Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

International Stem Cell (ISCO) Gains from Sales and Divestitures (2016 - 2018)

Historic Gains from Sales and Divestitures for International Stem Cell (ISCO) over the last 6 years, with Q4 2018 value amounting to $9855.0.

  • International Stem Cell's Gains from Sales and Divestitures fell 6783.93% to $9855.0 in Q4 2018 from the same period last year, while for Dec 2018 it was $9855.0, marking a year-over-year decrease of 6783.93%. This contributed to the annual value of $9855.0 for FY2018, which is 6783.93% down from last year.
  • Latest data reveals that International Stem Cell reported Gains from Sales and Divestitures of $9855.0 as of Q4 2018, which was down 6783.93% from $9855.0 recorded in Q3 2018.
  • International Stem Cell's 5-year Gains from Sales and Divestitures high stood at $299838.0 for Q1 2015, and its period low was $5527.0 during Q1 2018.
  • For the 5-year period, International Stem Cell's Gains from Sales and Divestitures averaged around $34605.5, with its median value being $13926.0 (2017).
  • As far as peak fluctuations go, International Stem Cell's Gains from Sales and Divestitures crashed by 9929.02% in 2014, and later surged by 18360.71% in 2016.
  • Over the past 5 years, International Stem Cell's Gains from Sales and Divestitures (Quarter) stood at $7309.0 in 2014, then soared by 180.68% to $20515.0 in 2015, then skyrocketed by 183.61% to $58182.0 in 2016, then tumbled by 47.33% to $30643.0 in 2017, then crashed by 67.84% to $9855.0 in 2018.
  • Its last three reported values are $9855.0 in Q4 2018, $9855.0 for Q3 2018, and $9855.0 during Q2 2018.